Search

Search Constraints

You searched for: Author/Creator Yumuk, Perran Fulden

Search Results

3. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Issue 3 (June 2021)

4. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. (9th August 2021)

5. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. (October 2020)

6. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. (June 2020)

7. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma. (30th June 2022)

8. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. (7th February 2021)

9. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Issue 21 (20th July 2021)

10. Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index. Issue 12 (20th September 2022)